Jay Gill II

Dr. Jay Gill II

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JIJay Gill II
Jay Gill II
JSJulia A. Schneiders
Julia A. Schneiders
MSMatthias Stangl
Matthias Stangl
ZAZahra M. Aghajan
Zahra M. Aghajan
MVMauricio Vallejo
Mauricio Vallejo
JLJean-Philippe Langevin
Jean-Philippe Langevin
The neurophysiological mechanisms in the human amygdala that underlie post-traumatic stress disorder (PTSD) remain poorly understood. In a first-of-its-kind pilot study, we recorded intracranial electroencephalographic data longitudinally (over one year) in two male individuals with amygdala electrodes implanted for the management of treatment-resistant PTSD (TR-PTSD) under clinical trial NCT04152993. To determine electrophysiological signatures related to emotionally aversive and clinically relevant states (trial primary endpoint), we characterized neural activity during unpleasant portions of three separate paradigms (negative emotional image viewing, listening to recordings of participant-specific trauma-related memories, and at-home-periods of symptom exacerbation). We found selective increases in amygdala theta (5–9 Hz) bandpower across all three negative experiences. Subsequent use of elevations in low-frequency amygdala bandpower as a trigger for closed-loop neuromodulation led to significant reductions in TR-PTSD symptoms (trial secondary endpoint) following one year of treatment as well as reductions in aversive-related amygdala theta activity. Altogether, our findings provide early evidence that elevated amygdala theta activity across a range of negative-related behavioral states may be a promising target for future closed-loop neuromodulation therapies in PTSD.

14 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JIJay Gill II
Jay Gill II
MOMahmoud Omidbeigi
Mahmoud Omidbeigi
JRJihye Ryu
Jihye Ryu
NSNanthia Suthana
Nanthia Suthana
JKJonathan C. Kao
Jonathan C. Kao
ABAusaf Bari
Ausaf Bari
Characterization of the neural basis of delay discounting provides insight into the origin of impulsive decision-making, which underlies several psychiatric diseases including substance use disorder. Here, we identify human single unit representations of decisions, and their level of difficulty, in the orbitofrontal cortex, hippocampus and amygdala that are related to preferences for immediate vs. delayed rewards. Results provide an initial account of multiregional intracranial computations related to impulsive behaviors in humans.

15 July 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
FLFred Lam
Fred Lam
ECEvan Alexander Chau
Evan Alexander Chau
YSYazhen Shi
Yazhen Shi
BMBryan Roel Martinez
Bryan Roel Martinez
AHAmar Hamdan
Amar Hamdan
SCSteven D Chang
Steven D Chang
Stereotactic radiosurgery (SRS) delivers high doses of focused ionizing radiation (IR) to a defined target while sparing surrounding tissues. The delivery of focused doses of IR has proven to be an effective modality for the treatment of brain tumors, cerebrovascular lesions, and primary neuropathic pain conditions. More recently, the emerging concept of “radiomodulation” to rewire neural circuitry through the delivery of focused IR to specific neural relay centers has emerged as an alternative way to treat neurological conditions, such as essential tremor, trigeminal neuralgia, and psychiatric illnesses. In this article, we performed a scoping review of the existing data supporting the ability of focused doses of ionizing radiation to achieve modulation of neural circuits for the treatment of neurological conditions. We review the current understanding of the neurophysiological mechanisms of radiomodulation, the gaps in knowledge limiting its widespread use for in-human applications and stress the unmet need for ongoing research to rigorously prove that radiomodulation may be the “final frontier” as a non-invasive, non-pharmacological, versatile, and tunable modality for the treatment of a multitude of neurological conditions.